Treatment Paradigm in NSCLC Treatment

More documents

Recommendations

Info

JMEN (maintenance pemetrexed):PFS and OS in ITT populationPatients with stage IIIB/IVNSCLC and PS 0–1 who hadreceived 4 previous cycles ofgemcitabine, docetaxel, orpaclitaxel + platinum with CR, PR,or SD (n=663)RANDOMISE2:1Pemetrexed 500mg/m 2 on d1q21d + BSC(n=441)Placebo on d1 q21d + BSC(n=222)PFS probability1.00.80.60.40.2PemetrexedPlaceboHR=0.60 (95% CI 0.49–0.73);p
Maintenance Pemetrexed : DFSBenefit of non-squamous histologyCiuleanu et al. Lancet 2009.
Page 2 and 3:
Which factors taken to beaccount in
Page 5:
Early stage (resectable disease)Adj
Page 9 and 10:
Stage I,II,III(except IA)
Page 11:
Confirm pathologic N2 (if possible)
Page 15 and 16: Which factors taken to beaccount in
Page 17 and 18: First line treatment in NSCLCASCODe
Page 23 and 24: Smoker adeno histologyNon smoker -
Page 25 and 26: Systemic Treatment Options inNSCLC
Page 27 and 28: Does histology matter ...For the se
Page 30: Smoker adeno histologyNon smoker -
Page 33 and 34: CONSORT: EfficacySurvivalMedian OS,
Page 35 and 36: EGFR expression in NSCLCxxxx
Page 37 and 38: Bevacizumab plus TCarb in non-squam
Page 39 and 40: EGFR expression in NSCLCEGFR TKIsxx
Page 45 and 46: Role of EGFR-TKIs in NSCLCClinical
Page 47 and 48: Mutations in EGFR TK inUnselected P
Page 49: At least 2 positive clinical factor
Page 54 and 55: Overall survival (ITT population)Ge
Page 56 and 57: EURTAC: First-line Erlotinib vs Che
Page 58 and 59: ASCO : RecommendationsECOG 0-1 :1 s
Page 60 and 61: 2004: pemetrexed versus docetaxel -
Page 62: Second line treatment in Advanced N
Page 65: Summary of available clinical evide
Page 69 and 70: 1st Line
Page 71 and 72: 1st Line2nd Line Docetaxel Docetaxe
show all

Treatment Paradigm in NSCLC Treatment

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?